Jazz Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Jazz Pharmaceuticals es Bruce Cozadd , nombrado en Jan 2003, tiene una permanencia de 21.83 años. compensación anual total es $15.34M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.52% de las acciones de la empresa, por valor de $37.58M. La antigüedad media del equipo directivo y de la junta directiva es de 5.2 años y 11.5 años, respectivamente.
Información clave
Bruce Cozadd
Chief Executive Officer (CEO)
US$15.3m
Compensación total
Porcentaje del salario del CEO | 7.8% |
Permanencia del CEO | 21.8yrs |
Participación del CEO | 0.5% |
Permanencia media de la dirección | 5.2yrs |
Promedio de permanencia en la Junta Directiva | 11.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$463m |
Jun 30 2024 | n/a | n/a | US$395m |
Mar 31 2024 | n/a | n/a | US$331m |
Dec 31 2023 | US$15m | US$1m | US$415m |
Sep 30 2023 | n/a | n/a | US$80m |
Jun 30 2023 | n/a | n/a | -US$87m |
Mar 31 2023 | n/a | n/a | -US$156m |
Dec 31 2022 | US$17m | US$1m | -US$224m |
Sep 30 2022 | n/a | n/a | -US$19m |
Jun 30 2022 | n/a | n/a | -US$52m |
Mar 31 2022 | n/a | n/a | -US$450m |
Dec 31 2021 | US$16m | US$1m | -US$330m |
Sep 30 2021 | n/a | n/a | -US$161m |
Jun 30 2021 | n/a | n/a | US$40m |
Mar 31 2021 | n/a | n/a | US$518m |
Dec 31 2020 | US$13m | US$1m | US$239m |
Sep 30 2020 | n/a | n/a | US$179m |
Jun 30 2020 | n/a | n/a | US$133m |
Mar 31 2020 | n/a | n/a | US$280m |
Dec 31 2019 | US$15m | US$1m | US$523m |
Sep 30 2019 | n/a | n/a | US$609m |
Jun 30 2019 | n/a | n/a | US$656m |
Mar 31 2019 | n/a | n/a | US$486m |
Dec 31 2018 | US$11m | US$979k | US$447m |
Sep 30 2018 | n/a | n/a | US$520m |
Jun 30 2018 | n/a | n/a | US$434m |
Mar 31 2018 | n/a | n/a | US$447m |
Dec 31 2017 | US$10m | US$950k | US$488m |
Compensación vs. Mercado: La compensación total de Bruce($USD15.34M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.94M).
Compensación vs. Ingresos: La compensación de Bruce ha sido consistente con los resultados de la empresa en el último año.
CEO
Bruce Cozadd (60 yo)
21.8yrs
Permanencia
US$15,341,235
Compensación
Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 21.8yrs | US$15.34m | 0.52% $ 37.6m | |
President & COO | 1.1yrs | US$5.43m | 0.028% $ 2.0m | |
Senior VP & Chief Accounting Officer | 5.3yrs | US$1.40m | sin datos | |
Executive VP & Chief Legal Officer | 5.3yrs | US$3.88m | 0.012% $ 879.4k | |
Executive VP | 5.5yrs | US$4.98m | 0.047% $ 3.4m | |
Executive VP & CFO | less than a year | sin datos | 0.020% $ 1.4m | |
VP & Head of Investor Relations | no data | sin datos | sin datos | |
Executive VP & Chief People Officer | 6yrs | sin datos | sin datos | |
Senior Vice President of Sleep & CNS Medicine | no data | sin datos | sin datos | |
Executive VP & Chief Commercial OfficerChief Commercial Officer | 4.7yrs | sin datos | 0.011% $ 763.4k | |
Senior Vice President of Corporate Strategy | 5.2yrs | sin datos | sin datos | |
Senior Vice President of Technical Operations | 1.3yrs | sin datos | 0.0021% $ 152.8k |
5.2yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de JAZZ es experimentado (5.2 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 21.8yrs | US$15.34m | 0.52% $ 37.6m | |
Independent Director | 20.8yrs | US$513.77k | 0.046% $ 3.3m | |
Independent Director | 12.8yrs | US$531.27k | 1.93% $ 139.4m | |
Independent Director | 11.5yrs | US$533.77k | 0.020% $ 1.5m | |
Independent Director | 15.3yrs | US$526.27k | 0.035% $ 2.5m | |
Independent Director | less than a year | sin datos | sin datos | |
Lead Independent Director | 14.5yrs | US$571.27k | 0.015% $ 1.1m | |
Independent Non-Executive Director | 3.9yrs | US$533.77k | 0.0089% $ 644.4k | |
Independent Director | less than a year | sin datos | 0.0025% $ 178.8k | |
Independent Director | 11.5yrs | US$543.77k | 0.025% $ 1.8m | |
Independent Non-Executive Director | 3.9yrs | US$521.27k | 0.0089% $ 644.4k | |
Independent Director | 5.8yrs | US$523.77k | 0.018% $ 1.3m |
11.5yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de JAZZ son experimentados ( 11.5 años antigüedad media).